A clinical trial comparing BiVap (Richard Wolf®) saline vaporization of the prostate vs. TwisterTM Diode Laser System in the treatment of benign prostatic obstruction between prostate volume 90 to 150?ml

Basit Öğe Kaydı
dc.authoridYasin Yitgin / 0000-0003-1111-6941en_US
dc.authoridAyhan Karaköse / 0000-0003-3905-1772
dc.authorscopusidYasin Yitgin / 56562977600
dc.authorscopusidAyhan Karaköse / 35769525800
dc.authorwosidYasin Yitgin / ABE-9487-2020
dc.authorwosidAyhan Karaköse / CXJ-8166-2022
dc.contributor.authorKaraköse, Ayhan
dc.contributor.authorYitgin, Yasin
dc.date.accessioned2022-01-18T10:27:40Z
dc.date.available2022-01-18T10:27:40Z
dc.date.issued2021en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.description.abstractIntroduction: To evaluate the efficacy, safety and postoperative outcomes of the BiVap and Twister systems with benign prostatic obstruction (BPO) in prostate volüm between 90–150?ml. Methods: In total, we included 131 patients treated with BiVap system (n = 68) and Twister system (n = 63). Postoperative complications including urinary tract infection, transient hematuria, severe dysuria and fever >38° C, urinary incontinence and urethral stricture were also noted. All patients were evaluated at the postoperative 1st, 3rd, 6th and 12th month and preoperative and postoperative values of IPSS score, QoL score, total PSA, IIEF 15, PVR, Qmax and Qave were compared. Results: Preoperative demographic characteristics were similar in the 2 groups. There was observed significant improvement for IPSS, Qmax, Qave, PVR, and QoL score by the postoperative first month compared to the preoperative values in both groups. Maximum improvement in the IPSS, Qmax, Qave, QoL score and PVR were achieved at postoperative 6, 3, 12, 3 and 12th months respectively in group 1. In group 2 maximum improvement in the same parameters were achieved at postoperative 6, 3, 6, 6 and 12th months, respectively. Conclusions: BiVap and Twister systems are safe, effective, and useful technique, which can be used in the surgical treatment of BPO between 90–150?mlen_US
dc.identifier.citationKarakose, A., & Yitgin, Y. (2021). A clinical trial comparing BiVap (richard wolf®) saline vaporization of the prostate vs. TwisterTM diode laser system in the treatment of benign prostatic obstruction between prostate volume 90 to 150 ml. Scottish Medical Journal, doi:10.1177/00369330211072262en_US
dc.identifier.doi10.1177/00369330211072262en_US
dc.identifier.issn0036-9330en_US
dc.identifier.scopus2-s2.0-85122159051en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1177/00369330211072262
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2397
dc.identifier.wosWOS:000738831500001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.institutionauthorKaraköse, Ayhan
dc.institutionauthorYitgin, Yasin
dc.language.isoenen_US
dc.publisherSAGE Publicationsen_US
dc.relation.ispartofScottish Medical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBiVapen_US
dc.subjectProstatic Obstructionen_US
dc.subjectTwisteren_US
dc.subjectVaporizationen_US
dc.titleA clinical trial comparing BiVap (Richard Wolf®) saline vaporization of the prostate vs. TwisterTM Diode Laser System in the treatment of benign prostatic obstruction between prostate volume 90 to 150?mlen_US
dc.typeArticleen_US

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Cerrahi Tıp Bilimleri Bölümü Makale Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu